Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: A randomized, double-blind study

Thomas Rappl, Daryousch Parvizi, Herwig Friedl, Maria Wiedner, Simone May, Bettina Kranzelbinder, Paul Wurzer, Bengt Hellbom

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration of treatment effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA for the treatment of glabellar frown lines. Subjects and methods: Subjects aged 20-60 years with moderate to severe glabellar frown lines received one treatment of either 21 units (U) incobotulinumtoxinA, 21 U onabotulinum-toxinA, or 63 U abobotulinumtoxinA. Assessments were made over a period of 180 days. Onset of treatment effect was defned as the day that the observer noted a decrease in glabellar muscle activity compared with baseline photographs and videos. Duration of treatment effect was defned as the time until glabellar muscle action returned to the baseline level. Analyses were performed using a Weibull log(T) regression model. Results: The study enrolled 180 subjects; 60 per group. For all three products, onset of treatment effect occurred earlier in female subjects compared to male subjects. For both sexes, a signifcantly earlier time to onset of treatment effect was seen for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; in female subjects these times were 3.02 days, 5.29 days, and 5.32 days, respectively. The duration of treatment effect was longer for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; for all products, treatment effect duration was longer in females than in males. Time to onset was not a predictor of treatment duration. Conclusion: IncobotulinumtoxinA demonstrated a more rapid onset and a longer duration of treatment effect than onabotulinumtoxinA (1:1 dose ratio) and abobotulinumtoxinA (1:3 dose ratio). Onset of effect was faster and duration of effect was longer in female subjects compared to male subjects.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalClinical, Cosmetic and Investigational Dermatology
Volume6
DOIs
StatePublished - Sep 23 2013
Externally publishedYes

Fingerprint

Double-Blind Method
Muscles
Type A Botulinum Toxins
onabotulinumtoxinA
abobotulinumtoxinA
incobotulinumtoxinA

Keywords

  • Botulinum neurotoxin type A
  • Glabellar frown lines
  • IncobotulinumtoxinA
  • Regression analysis

ASJC Scopus subject areas

  • Dermatology

Cite this

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines : A randomized, double-blind study. / Rappl, Thomas; Parvizi, Daryousch; Friedl, Herwig; Wiedner, Maria; May, Simone; Kranzelbinder, Bettina; Wurzer, Paul; Hellbom, Bengt.

In: Clinical, Cosmetic and Investigational Dermatology, Vol. 6, 23.09.2013, p. 211-219.

Research output: Contribution to journalArticle

Rappl, Thomas ; Parvizi, Daryousch ; Friedl, Herwig ; Wiedner, Maria ; May, Simone ; Kranzelbinder, Bettina ; Wurzer, Paul ; Hellbom, Bengt. / Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines : A randomized, double-blind study. In: Clinical, Cosmetic and Investigational Dermatology. 2013 ; Vol. 6. pp. 211-219.
@article{0a72a6b2a76e412f9a76008d602c4638,
title = "Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: A randomized, double-blind study",
abstract = "Background: Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration of treatment effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA for the treatment of glabellar frown lines. Subjects and methods: Subjects aged 20-60 years with moderate to severe glabellar frown lines received one treatment of either 21 units (U) incobotulinumtoxinA, 21 U onabotulinum-toxinA, or 63 U abobotulinumtoxinA. Assessments were made over a period of 180 days. Onset of treatment effect was defned as the day that the observer noted a decrease in glabellar muscle activity compared with baseline photographs and videos. Duration of treatment effect was defned as the time until glabellar muscle action returned to the baseline level. Analyses were performed using a Weibull log(T) regression model. Results: The study enrolled 180 subjects; 60 per group. For all three products, onset of treatment effect occurred earlier in female subjects compared to male subjects. For both sexes, a signifcantly earlier time to onset of treatment effect was seen for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; in female subjects these times were 3.02 days, 5.29 days, and 5.32 days, respectively. The duration of treatment effect was longer for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; for all products, treatment effect duration was longer in females than in males. Time to onset was not a predictor of treatment duration. Conclusion: IncobotulinumtoxinA demonstrated a more rapid onset and a longer duration of treatment effect than onabotulinumtoxinA (1:1 dose ratio) and abobotulinumtoxinA (1:3 dose ratio). Onset of effect was faster and duration of effect was longer in female subjects compared to male subjects.",
keywords = "Botulinum neurotoxin type A, Glabellar frown lines, IncobotulinumtoxinA, Regression analysis",
author = "Thomas Rappl and Daryousch Parvizi and Herwig Friedl and Maria Wiedner and Simone May and Bettina Kranzelbinder and Paul Wurzer and Bengt Hellbom",
year = "2013",
month = "9",
day = "23",
doi = "10.2147/CCID.S41537",
language = "English (US)",
volume = "6",
pages = "211--219",
journal = "Clinical, Cosmetic and Investigational Dermatology",
issn = "1178-7015",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines

T2 - A randomized, double-blind study

AU - Rappl, Thomas

AU - Parvizi, Daryousch

AU - Friedl, Herwig

AU - Wiedner, Maria

AU - May, Simone

AU - Kranzelbinder, Bettina

AU - Wurzer, Paul

AU - Hellbom, Bengt

PY - 2013/9/23

Y1 - 2013/9/23

N2 - Background: Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration of treatment effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA for the treatment of glabellar frown lines. Subjects and methods: Subjects aged 20-60 years with moderate to severe glabellar frown lines received one treatment of either 21 units (U) incobotulinumtoxinA, 21 U onabotulinum-toxinA, or 63 U abobotulinumtoxinA. Assessments were made over a period of 180 days. Onset of treatment effect was defned as the day that the observer noted a decrease in glabellar muscle activity compared with baseline photographs and videos. Duration of treatment effect was defned as the time until glabellar muscle action returned to the baseline level. Analyses were performed using a Weibull log(T) regression model. Results: The study enrolled 180 subjects; 60 per group. For all three products, onset of treatment effect occurred earlier in female subjects compared to male subjects. For both sexes, a signifcantly earlier time to onset of treatment effect was seen for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; in female subjects these times were 3.02 days, 5.29 days, and 5.32 days, respectively. The duration of treatment effect was longer for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; for all products, treatment effect duration was longer in females than in males. Time to onset was not a predictor of treatment duration. Conclusion: IncobotulinumtoxinA demonstrated a more rapid onset and a longer duration of treatment effect than onabotulinumtoxinA (1:1 dose ratio) and abobotulinumtoxinA (1:3 dose ratio). Onset of effect was faster and duration of effect was longer in female subjects compared to male subjects.

AB - Background: Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration of treatment effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA for the treatment of glabellar frown lines. Subjects and methods: Subjects aged 20-60 years with moderate to severe glabellar frown lines received one treatment of either 21 units (U) incobotulinumtoxinA, 21 U onabotulinum-toxinA, or 63 U abobotulinumtoxinA. Assessments were made over a period of 180 days. Onset of treatment effect was defned as the day that the observer noted a decrease in glabellar muscle activity compared with baseline photographs and videos. Duration of treatment effect was defned as the time until glabellar muscle action returned to the baseline level. Analyses were performed using a Weibull log(T) regression model. Results: The study enrolled 180 subjects; 60 per group. For all three products, onset of treatment effect occurred earlier in female subjects compared to male subjects. For both sexes, a signifcantly earlier time to onset of treatment effect was seen for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; in female subjects these times were 3.02 days, 5.29 days, and 5.32 days, respectively. The duration of treatment effect was longer for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; for all products, treatment effect duration was longer in females than in males. Time to onset was not a predictor of treatment duration. Conclusion: IncobotulinumtoxinA demonstrated a more rapid onset and a longer duration of treatment effect than onabotulinumtoxinA (1:1 dose ratio) and abobotulinumtoxinA (1:3 dose ratio). Onset of effect was faster and duration of effect was longer in female subjects compared to male subjects.

KW - Botulinum neurotoxin type A

KW - Glabellar frown lines

KW - IncobotulinumtoxinA

KW - Regression analysis

UR - http://www.scopus.com/inward/record.url?scp=84884561123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884561123&partnerID=8YFLogxK

U2 - 10.2147/CCID.S41537

DO - 10.2147/CCID.S41537

M3 - Article

C2 - 24098087

AN - SCOPUS:84884561123

VL - 6

SP - 211

EP - 219

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -